Cambridge Epigenetix

Our starting point is TrueMethylTM oxidative bisulfite sequencing (oxBS-Seq), a novel technology that pioneers quantitative, single-base resolution sequencing of the modified bases hydroxymethyl cytosine (5-hmC) and methylcytosine (5-mC). TrueMethyl enables analysis of the DNA methylome with unprecdented accuracy and opens new avenues for basic research, pharmaceutical discovery and diagnostics. Recent studies have shown that at some sites in the genome the level of 5-hmC can be comparable to the level of 5-mC, emphasizing the importance of identifying these variants accurately. However, traditional bisulfite sequencing cannot discriminate between 5-hmC and 5-mC. Co-invented by Prof. Shankar Balasubramanian, who previously co-invented the Solexa / Illumina sequencing-by-synthesis platform, and Michael Booth, innovative oxBS-Seq technology utilises a selective chemical oxidation that accurately distinguishes between 5-mC and 5-hmC. TrueMethyl can be used with a variety of common platforms including next generation sequencing systems, methylation arrays, and targeted assays. Employing chemical oxidation gives very high conversion efficiencies and minimises sequence context effects, giving results of unparalleled quality. TrueMethyl enables: Quantitative measurement of 5-hmC and 5-mC in parallel Single-base resolution methylation and hydroxymethylation analysis Confirmation of the location of unmethylated cytosines CEGX is funded by Syncona Partners as well as Cambridge Enterprise and our management team comprises industry leaders and epigenetics expertise.
Company Growth (employees)
Type
Private
HQ
Great Shelford, GB
Founded
2012
Size (employees)
29 (est)-6%
Cambridge Epigenetix was founded in 2012 and is headquartered in Great Shelford, GB

Key People/Management at Cambridge Epigenetix

Shankar Balasubramian

Shankar Balasubramian

Co-Founder and Director
Jason Mellad

Jason Mellad

Business Development Manager
Mike Booth

Mike Booth

Research Scientist

Cambridge Epigenetix Office Locations

Cambridge Epigenetix has an office in Great Shelford
Great Shelford, GB (HQ)
Focus School - Cambridge Campus

Cambridge Epigenetix Financials and Metrics

Summary Metrics

Founding Date

2012

Total Funding

$26.5 m

Latest funding size

$21 m

Time since last funding

over 1 year

Investors

Cambridge Epigenetix's latest funding round in March 2016 was reported to be $21 m. In total, Cambridge Epigenetix has raised $26.5 m

Cambridge Epigenetix Financials

GBP

Net income (FY, 2012)

(86.2 k)

Cash (31-Dec-2016)

10.8 m
GBPFY, 2012

Pre tax profit

(86.2 k)

Net Income

(86.2 k)
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

482.1 k202.3 k1.5 m967.3 k10.8 m

Accounts Receivable

77.3 k1.7 m67.2 k31.2 k

Inventories

56.9 k35.7 k54.6 k80.3 k

Current Assets

497.9 k336.5 k3.3 m1.3 m11.1 m
    GBPFY, 2012

    Net Income

    (86.2 k)
      Y, 2016

      Financial Leverage

      1 x
      Show all financial metrics

      Cambridge Epigenetix's Web-traffic and Trends

      Cambridge Epigenetix Online and Social Media Presence

      Cambridge Epigenetix Company Life and Culture

      You may also be interested in